Pfizer Inc.

XNYSHealth care

Last traded price · USD

$30.90

+3.00%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:29 IST · A quote does not mean the product is available to trade on your account.

Day's open: $30.75
Previous close: $30.00
Volume: 49.9M
Day's high: $30.90
Day's low: $30.04

In brief

Pfizer Inc. is a health care company listed on the New York Stock Exchange, valued at about $176.11B.
Its shares closed at $30.79 on 4 Nov 2026, up 26.7% over the past year.
From India you can buy PFE in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Pfizer Inc. (PFE) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole PFE share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade PFE options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

0.9% below its 52-week high
Closed at $30.79 on 4 Nov 2026: 0.9% below the 52-week high of $31.06 (3 Nov 2026) and 30.4% above the low of $23.62 (6 Jul 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +12.0% (SPY −1.6%, XLV +13.5%). 3 months: +19.3% (SPY −0.4%, XLV +15.5%). 1 year: +26.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PFE, SPY and XLV · as of 4 Nov 2026
Next ex-dividend date: 6 Nov 2026
$0.43 a share, payable 7 Dec 2026; unchanged from the previous payment (ex-date 24 Jul 2026).
Corporate actions record · as of 5 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $30.79 was 7.3% above its 50-day average ($28.68) and 14.6% above its 200-day average ($26.87). It has closed above the 200-day for 64 sessions, since 6 Aug 2026. The 50-day average crossed above the 200-day on 11 Sep 2026, 38 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
P/E 11.1% below its peers' median
Trailing P/E of 40.7 against a median of 45.7 across 5 peers named in its company record (range 13.7 to 115.7).
Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+12.0%

6 months+16.1%

1 year+26.7%

5 years−29.8%

Newswire

About

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

Website

Notable moves

October 1, 2025
+6.79%
September 30, 2025
+6.83%
November 5, 2021
+10.86%

Newswire

About

Website

Notable moves

October 1, 2025
+6.79%
September 30, 2025
+6.83%
November 5, 2021
+10.86%

Pfizer Inc.

XNYSHealth care

Last traded price · USD

$30.90

+3.00%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:29 IST · A quote does not mean the product is available to trade on your account.

Day's open: $30.75
Previous close: $30.00
Volume: 49.9M
Day's high: $30.90
Day's low: $30.04

In brief

Pfizer Inc. is a health care company listed on the New York Stock Exchange, valued at about $176.11B.
Its shares closed at $30.79 on 4 Nov 2026, up 26.7% over the past year.
From India you can buy PFE in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Pfizer Inc. (PFE) shares from India?

Do I need the price of a whole PFE share to invest?

How much can I invest in US stocks in a year?

Can I trade PFE options or futures?

Insights

Quotes run fifteen minutes behind.

0.9% below its 52-week high
Closed at $30.79 on 4 Nov 2026: 0.9% below the 52-week high of $31.06 (3 Nov 2026) and 30.4% above the low of $23.62 (6 Jul 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +12.0% (SPY −1.6%, XLV +13.5%). 3 months: +19.3% (SPY −0.4%, XLV +15.5%). 1 year: +26.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PFE, SPY and XLV · as of 4 Nov 2026
Next ex-dividend date: 6 Nov 2026
$0.43 a share, payable 7 Dec 2026; unchanged from the previous payment (ex-date 24 Jul 2026).
Corporate actions record · as of 5 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $30.79 was 7.3% above its 50-day average ($28.68) and 14.6% above its 200-day average ($26.87). It has closed above the 200-day for 64 sessions, since 6 Aug 2026. The 50-day average crossed above the 200-day on 11 Sep 2026, 38 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
P/E 11.1% below its peers' median
Trailing P/E of 40.7 against a median of 45.7 across 5 peers named in its company record (range 13.7 to 115.7).
Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+12.0%

6 months+16.1%

1 year+26.7%

5 years−29.8%

Newswire

About

Website

Notable moves

October 1, 2025
+6.79%
September 30, 2025
+6.83%
November 5, 2021
+10.86%

Newswire

About

Website

Notable moves

October 1, 2025
+6.79%
September 30, 2025
+6.83%
November 5, 2021
+10.86%

Pfizer Inc.

Pfizer Inc. in brief

0.9% below its 52-week high

Ahead of SPY, behind its sector fund XLV over 1 year

Next ex-dividend date: 6 Nov 2026

Above its 50- and 200-day averages

P/E 11.1% below its peers' median

Pfizer Inc.

Pfizer Inc. in brief

0.9% below its 52-week high

Ahead of SPY, behind its sector fund XLV over 1 year

Next ex-dividend date: 6 Nov 2026

Above its 50- and 200-day averages

P/E 11.1% below its peers' median